Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

Johns Hopkins University11 enrolled

Overview

This research is being done to learn how seminal fluid affects the lining of the colon, and whether this might make it easier for HIV to get into the body and cause infection.

Design of effective rectal microbicides to prevent HIV infection requires an understanding of rectal HIV transmission and the location within the lower gastrointestinal (GI) tract (luminal and mucosal) of HIV (cell-free and cell-associated) following exposure to infected seminal fluid. These basic details of HIV transmission have yet to be determined in human subjects, yet they are essential to select microbicide candidates if they are to be rationally designed to achieve effective concentrations at sites of HIV transmission. Rational development of a rectal microbicide also requires an understanding of those factors that may contribute to colonic mucosal injury - potential confounders of microbicidal effect. Such factors include exposure to seminal fluid which has been shown in animal and in vitro studies to cause histologic and permeability changes that might facilitate HIV transmission.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

Radiolabeled autologous seminal fluidBIOLOGICAL

Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.

Radiolabeled Normosol-RBIOLOGICAL

Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.

Eligibility

Sex: MALEMin age: 21 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Able to provide signed informed consent * Men of 21 years or older. * Prior history of receptive anal intercourse. * Laboratory values within the last 28 days: * Negative for HIV antibodies * Lymphocyte count within normal limits * Neutrophil count \> 1,000 cells/ml * Cluster of Differentiation 4 (CD4) cell count \> 500 cells/ml * Platelet count ≥ 150,000 cells/mm3 * Prothrombin Time (PT) within normal limits * Partial thromboplastin time (PTT) within normal limits. * No childbearing intentions. Exclusion Criteria: * Active anorectal disease or recent (3 months) anorectal surgery; * Diarrhea, defined as three or more loose stools per day, for at least three days prior to admission. * History of sleep apnea, or airway problems with previous sedation procedures. * History of significant adverse reaction to sedation medications. * Other history, including significant occupational radiation exposure, history of inflammatory bowel disease or any other diseases and lab results, such that, in the judgment of the investigator, study procedures are not considered safe for the subject's participation.

Locations (1)

Johns Hopkins University Drug Development Unit

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Epithelial Disruption Graded by a Pathologist Blinded to Study Intervention.

Endoscopy will be performed to obtain biopsy specimens at baseline and following each inpatient enema exposure. Samples will be obtained at each flexible sigmoidoscopy and set aside for batch sectioning and H\&E staining. Slides will be reviewed and scored by a qualified pathologist blinded to treatment assignment using a qualitative scoring system. This scoring system uses semi-quantitative scoring that focuses on acute toxicity to epithelial cell layer similar to that seen in animal studies. This is a categorical grading scale, where 0 = Epithelial surface intact;1 = \<1/3 of surface denuded; 2 = 1/3 - 2/3rds of surface denuded;3 = More than 2/3rds of surface denuded. Six separate biopsies for each subject and each treatment intervention were analyzed in a multi-level analysis. In comparison with the baseline condition (no intervention), the odds and 95% confidence interval (CI) of having a higher epithelial denudation score were calculated for each intervention.

Time frame: One hour

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.